

Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis


SUPPLEMENTARY MATERIALS


Supplementary Table 1: Reported unadjusted vs. adjusted survival estimates

Name	Year	Biomarker	Survival Type	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
O'Callaghan	2015	CD3	OS	0.70 (0.47-1.05)	0.65 (0.41-1.02)
Sepesi	2017	CD3	OS	0.60 (0.32-1.12)	0.35 (0.11-1.09)
Sepesi	2017	CD4	os	0.49 (0.29-0.85)	0.35 (0.11-1.09)
Matsubara	2019	CD4	OS	1.55 (1.03-2.37)	1.65 (1.07–2.55)
O'Callaghan	2015	CD8	OS	0.44 (0.29-0.67)	0.48 (0.30-0.76)
Yazdi	2016	CD8	OS	0.64 (0.40-1.04)	0.62 (0.38-1.01)
Ameratunga	2016	CD8	DFS	0.82 (0.64-1.04)	0.70 (0.50-0.97)
Teng	2016	CD8	os	0.51 (0.29-0.98)	0.54 (0.28–1.05)
Teng	2016	CD8	DFS	0.39 (0.22-0.71)	0.22 (0.05-0.89)
Ye	2017	CD8	os	0.71 (0.52-0.99)	0.70 (0.44-1.10)
Kinoshita	2017	CD8	DFS	2.92 (1.69-5.07)	2.01 (1.14–3.56)
Sepesi	2017	CD8	OS	1.88 (0.82–3.34)	1.70 (0.40–7.45)
Kinoshita	2016	CD20	DFS	0.53 (0.34-0.84)	0.51 (0.32-0.80)
Villegas	2002	CD57	OS	0.43 (0.20-0.95)	0.40 (0.17-0.93)
Sepesi	2017	CD57	OS	0.24 (0.03-1.70)	0.60 (0.05-6.51)
Kojima	2002	CD68	OS	1.45 (0.71–2.97)	1.43 (0.66–3.09)
Sepesi	2017	CD68	os	0.35 (0.12-0.97)	0.79 (0.11-5.63)
Cao	2019	CD68	OS	4.19 (1.90-9.27)	2.86 (1.13-7.26)
Cao	2019	CD68	DFS	2.09 (1.26-3.46)	1.81 (1.09-3.02)
Hanagiri	2013	FoxP3	os	2.56 (1.28-5.10)	1.82 (0.90-3.69)
Hanagiri	2014	FoxP3	OS	2.82 (1.00-7.93)	4.22 (1.11-5.56)
O'Callaghan	2015	FoxP3	OS	4.86 (3.11–7.59)	3.91 (2.33-6.55)
Barua	2018	FoxP3	os	1.43 (0.63-3.21)	1.52 (1.11–2.07)
Kojima	2002	Mast Cells	OS	2.31 (1.09–4.89)	1.16 (0.51-2.67)
Pelosi	2004	Mast Cells	OS	2.30 (1.20-4.90)	1.70 (0.60-4.60)
Pelosi	2004	Mast Cells	DFS	2.30 (1.20-4.70)	1.50 (0.60-3.60)
Kojima	2005	Mast Cells	OS	2.04 (1.05-3.96)	1.15 (0.53-2.48)













Supplementary Figure 1: (A) Forest Plot of CD3+T Cells. (B) Funnel Plot of CD3+T Cells Unadjusted OS Studies. (C) Funnel Plot of CD3+T Cells Adjusted OS Studies. (D) Funnel Plot of CD3+T Cells Unadjusted DFS Studies.













Supplementary Figure 2: (**A**) Forest Plot of CD4+ T Helper cells. (**B**) Funnel Plot of CD4+ T Helper cells Unadjusted OS Studies. (**C**) Funnel Plot of CD4+ T Helper cells Adjusted OS Studies. (**D**) Funnel Plot of CD4+ T Helper cells Unadjusted DFS Studies.


CD8+ T cytotoxic cells













Supplementary Figure 3: (**A**) Forest Plot of CD8+ T cytotoxic cells. (**B**) Funnel Plot of CD8+ T cytotoxic cells Unadjusted OS Studies. (**C**) Funnel Plot of CD8+ T cytotoxic cells Adjusted OS Studies. (**E**) Funnel Plot of CD8+ T cytotoxic cells Adjusted DFS Studies. (**E**) Funnel Plot of CD8+ T cytotoxic cells Adjusted DFS Studies.





 $Supplementary \ Figure \ 4: (A) \ Forest \ Plot \ of \ CD20+B \ cells. (B) \ Funnel \ Plot \ of \ CD20+B \ cells \ Unadjusted \ OS \ Studies. (C) \ Funnel \ Plot \ of \ CD20+B \ cells \ Unadjusted \ DFS \ Studies.$


Observed Outcome


0


-1


0.771


-2















Supplementary Figure 5: (A) Forest Plot of FoxP3+T Regulatory cells. (B) Funnel Plot of FoxP3+T Regulatory cells Unadjusted OS Studies. (C) Funnel Plot of FoxP3+T Regulatory cells Adjusted OS Studies. (D) Funnel Plot of FoxP3+T Regulatory cells Unadjusted DFS Studies. (E) Funnel Plot of FoxP3+T Regulatory cells Adjusted DFS Studies.










 $\textbf{Supplementary Figure 6: (A)} \ \ \text{Forest Plot of NK cells (CD56/CD57+). (B)} \ \ \text{Funnel Plot of NK cells (CD56/CD57+)} \ \ \text{Unadjusted OS Studies.}$ $\textbf{Studies. (C)} \ \ \text{Funnel Plot of NK cells (CD56/CD57+)} \ \ \text{Adjusted OS Studies.}$










Supplementary Figure 7: (A) Forest Plot of macrophages (CD68+). (B) Funnel Plot of macrophages (CD68+) Unadjusted OS Studies. (C) Funnel Plot of macrophages (CD68+) Adjusted OS Studies. (D) Funnel Plot of macrophages (CD68+) Adjusted DFS Studies.

Study	Н	azard Ratio [95% CI]			
Overall Survival Unadjusted Kojima, 2005 Pelosi, 2004 Kojima, 2002 Kojima, 2002 Random Effects I ² = 43.99% Q = 5.36; (p = 0.15)		2.04 [0.65, 6.38] 2.30 [0.69, 7.71] 1.79 [0.40, 7.99] 2.31 [0.69, 7.77] 2.01 [0.88, 4.62]			
Adjusted Kojima, 2005 Pelosi, 2004 Kojima, 2002 Takanami, 2000 Random Effects I ² = 0.00% Q = 0.09; (p = 0.99)		1.15 [0.34, 3.92] 1.70 [0.41, 6.98] 1.16 [0.32, 4.17] → 5.97 [2.00, 17.78] 2.13 [1.14, 3.96]			
Disease Free Survival Unadjusted Pelosi, 2004		2.30 [0.72, 7.31]			
Adjusted Pelosi, 2004	-	1.50 [0.40, 5.64]			
0.	05 0.15 1 2.5 5 10	30			
Hazard Ratio (log scale)					



 $\textbf{Supplementary Figure 8: (A)} \ \text{Forest Plot of MCs. (B)} \ \text{Funnel Plot of MCs Unadjusted OS Studies. (C)} \ \text{Funnel Plot of MCs Adjusted OS Studies.}$

0.5

Observed Outcome

1

1.5

2

2.5

0.721

-1

-0.5

0